Clinical Outcome of Treatment of Ulcerative Colitis in Adult

NCT06143163 | Unknown

• 1 other identifier: Treatment of UC
• Study Type: observational
• Target: 162
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.characterize the response to current medical therapy in adult with ulcerative colitis .
2. 2.Detect prognostic factors of response of biological therapy in adult with ulcerative colitis

Conditions

Ulcerative Colitis

Outcome Measures

Primary Outcomes (1)

• - Characterize the response to current medical therapy in adult with Ulcerative colitis

  The clinical course of the disease Will be assessed after 3 months of treatment according to guidelines as follow 1. clinical assessment as regard symptoms as rectal bleeding, diarrhea, abdominal pain, stool frequency guided by mayo score. 2. laboratory assessment including: ESR,CRP,CBC,fecalcalprotectin. 3. Endoscopic evaluation regarding the mayo score. 4. Histopathological assessment to evaluate the stage of activity of the disease.

  Baseline

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

1. diagnosed by colonscopy and biobsy with ulcerative colitis . 2. must be above 18yrs.

You may qualify if:

• All Patients above age of 18 years old previously diagnosed by colonscopy and biobsy with ulcerative colitis attending IBD clinic El-Raghy liver Hospital

You may not qualify if:

• patients younger than 18 years old .
• patients known to have chronic liver disease.
• patient known to have renal disease.
• Patients diagnosed with cardiac disease.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (10)

• Gisbert JP, Chaparro M. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. J Crohns Colitis. 2019 Mar 26;13(3):374-384. doi: 10.1093/ecco-jcc/jjy158.

  PMID: 30307487 BACKGROUND

• Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1079-1100. doi: 10.1080/17474124.2018.1530109. Epub 2018 Oct 17.

  PMID: 30284911 BACKGROUND

• Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. World J Gastroenterol. 2018 Sep 21;24(35):4014-4020. doi: 10.3748/wjg.v24.i35.4014.

  PMID: 30254405 BACKGROUND

• Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health. 2017 Oct;1(2):147-158. doi: 10.1016/S2352-4642(17)30017-2. Epub 2017 Aug 7.

  PMID: 30169204 BACKGROUND

• Guardiola J, Lobaton T, Cerrillo E, Ferreiro-Iglesias R, Gisbert JP, Domenech E, Chaparro M, Esteve M, Rodriguez-Moranta F; en representacion de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol. 2018 Oct;41(8):514-529. doi: 10.1016/j.gastrohep.2018.05.029. Epub 2018 Jul 4. English, Spanish.

  PMID: 30293556 BACKGROUND

• Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2019 Mar;52(2):129-136. doi: 10.5946/ce.2018.042. Epub 2018 Aug 21.

  PMID: 30130840 BACKGROUND

• Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res. 2018 Oct;16(4):522-528. doi: 10.5217/ir.2018.00073. Epub 2018 Oct 16.

  PMID: 30321913 BACKGROUND

• Rodriguez-Lago I, Ferreiro-Iglesias R, Nos P, Gisbert JP; en representacion del Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. Gastroenterol Hepatol. 2019 Feb;42(2):90-101. doi: 10.1016/j.gastrohep.2018.09.002. Epub 2018 Oct 4. English, Spanish.

  PMID: 30293913 BACKGROUND

• Borman ZA, Cote-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1101-1108. doi: 10.1080/17474124.2018.1530983. Epub 2018 Oct 10.

  PMID: 30277409 BACKGROUND

• Drews JD, Onwuka EA, Fisher JG, Huntington JT, Dutkiewicz M, Nogalska A, Nwomeh BC. Complications after proctocolectomy and ileal pouch-anal anastomosis in pediatric patients: A systematic review. J Pediatr Surg. 2019 Jul;54(7):1331-1339. doi: 10.1016/j.jpedsurg.2018.08.047. Epub 2018 Sep 19.

  PMID: 30291026 BACKGROUND

MeSH Terms

Conditions

Colitis, Ulcerative

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr kholoud Mohamed Hassan

Study Record Dates

• First Submitted: November 5, 2023
• First Posted: November 22, 2023
• Study Start: December 29, 2024
• Primary Completion: December 29, 2025
• Study Completion: January 29, 2026
• Last Updated: November 22, 2023

Record last verified: 2023-11